focus -WSS

focus

author：Wikipedia 2025-09-05 07:02:27 - browse：1853

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： General Catalyst, Summa Health deal will turn on physician buy

leisure time

knowledge

WSS

South Korea throws huge K

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

In same hospitals, Black patients receive fewer opioids than white patients

New Ultima Genomics DNA sequencer can read genome for $100

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Biden administration opens offers in Medicare drug price negotiations

hotspot

focus

focus

Supreme Court strikes down use of affirmative action

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

In age of alternative facts, a scholarly course on calling out crap

For Cytokinetics, FDA rejection of heart drug would help, not hinder

As demand for Covid shots wanes, Moderna seeks its next success

NIH trials fail to test meaningful long Covid therapies, experts say

Psychedelics group wrestles with new pharma identity

SAMSHA loosens regulations on methadone treatment centers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Naloxone nonprofit donates 200,000 doses after FDA approval

entertainment

Wegovy’s successful heart trial raises vital question about weight loss

In same hospitals, Black patients receive fewer opioids than white patients

NIH trials fail to test meaningful long Covid therapies, experts say

Drastic changes should bring profitability, startup health insurers say

Police still searching for prisoner who escaped from NYC hospital

Apple Vision Pro: A first look at health apps on the new VR headset

focus

leisure time

knowledge

focus